PTC Therapeutics, Inc. Revenue
PTC Therapeutics, Inc. (PTCT) reported Revenue of $360.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $360.52M, a 101.55% increase year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $272.55M, a 76.83% decline year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $164.68M, a 22.75% decline year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $211.01M, a 7.23% increase year-over-year.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.73B, a 114.51% increase from fiscal 2024.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $806.78M, a 13.97% decline from fiscal 2023.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $937.82M, a 34.20% increase from fiscal 2022.
- PTC Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $698.80M, a 29.75% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $360.52M 10-Q · filed 2026-07-30 | $633.07M 10-Q · filed 2026-07-30 | $797.75M derived: sum of 3 quarters · filed 2026-07-30 | $1.01B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $272.55M 10-Q · filed 2026-05-07 | $437.23M derived: sum of 2 quarters · filed 2026-05-07 | $648.24M derived: sum of 3 quarters · filed 2026-05-07 | $827.11M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $164.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $375.68M derived: sum of 2 quarters · filed 2026-02-19 | $554.56M derived: sum of 3 quarters · filed 2026-07-30 | $1.73B 10-K · filed 2026-02-19 |
| 2025-09-30 | $211.01M 10-Q · filed 2025-11-04 | $389.88M derived: sum of 2 quarters · filed 2026-07-30 | $1.57B 10-Q · filed 2025-11-04 | $1.78B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $178.88M 10-Q · filed 2026-07-30 | $1.35B 10-Q · filed 2026-07-30 | $1.57B derived: sum of 3 quarters · filed 2026-07-30 | $1.76B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.18B 10-Q · filed 2026-05-07 | $1.39B derived: sum of 2 quarters · filed 2026-05-07 | $1.59B derived: sum of 3 quarters · filed 2026-05-07 | $1.77B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $213.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $409.96M derived: sum of 2 quarters · filed 2026-02-19 | $596.66M derived: sum of 3 quarters · filed 2026-02-19 | $806.78M 10-K · filed 2026-02-19 |
| 2024-09-30 | $196.79M 10-Q · filed 2025-11-04 | $383.49M derived: sum of 2 quarters · filed 2025-11-04 | $593.61M 10-Q · filed 2025-11-04 | $900.66M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $186.70M 10-Q · filed 2025-08-07 | $396.82M 10-Q · filed 2025-08-07 | $703.88M derived: sum of 3 quarters · filed 2026-02-19 | $900.45M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $210.12M 10-Q · filed 2025-05-06 | $517.17M derived: sum of 2 quarters · filed 2026-02-19 | $713.75M derived: sum of 3 quarters · filed 2026-02-19 | $927.56M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $307.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $503.63M derived: sum of 2 quarters · filed 2026-02-19 | $717.44M derived: sum of 3 quarters · filed 2026-02-19 | $937.82M 10-K · filed 2026-02-19 |
| 2023-09-30 | $196.58M 10-Q · filed 2024-11-07 | $410.38M derived: sum of 2 quarters · filed 2024-11-07 | $630.77M 10-Q · filed 2024-11-07 | $798.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $213.81M 10-Q · filed 2024-08-08 | $434.19M 10-Q · filed 2024-08-08 | $601.60M derived: sum of 3 quarters · filed 2025-02-27 | $818.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $220.38M 10-Q · filed 2024-04-25 | $387.79M derived: sum of 2 quarters · filed 2025-02-27 | $604.92M derived: sum of 3 quarters · filed 2025-02-27 | $770.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $167.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $384.54M derived: sum of 2 quarters · filed 2025-02-27 | $550.07M derived: sum of 3 quarters · filed 2025-02-27 | $698.80M 10-K · filed 2025-02-27 |
| 2022-09-30 | $217.13M 10-Q · filed 2023-10-26 | $382.65M derived: sum of 2 quarters · filed 2023-10-26 | $531.39M 10-Q · filed 2023-10-26 | $696.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $165.53M 10-Q · filed 2023-08-03 | $314.26M 10-Q · filed 2023-08-03 | $479.49M derived: sum of 3 quarters · filed 2024-02-29 | $618.23M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $148.74M 10-Q · filed 2023-04-27 | $313.96M derived: sum of 2 quarters · filed 2024-02-29 | $452.71M derived: sum of 3 quarters · filed 2024-02-29 | $569.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $165.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $303.97M derived: sum of 2 quarters · filed 2024-02-29 | $420.65M derived: sum of 3 quarters · filed 2024-02-29 | $538.59M 10-K · filed 2024-02-29 |
| 2021-09-30 | $138.74M 10-Q · filed 2022-10-27 | $255.42M derived: sum of 2 quarters · filed 2022-10-27 | $373.36M 10-Q · filed 2022-10-27 | $492.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $116.68M 10-Q · filed 2022-08-04 | $234.62M 10-Q · filed 2022-08-04 | $353.48M derived: sum of 3 quarters · filed 2023-02-21 | $471.89M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $117.94M 10-Q · filed 2022-05-03 | $236.81M derived: sum of 2 quarters · filed 2023-02-21 | $355.21M derived: sum of 3 quarters · filed 2023-02-21 | $430.45M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $118.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $237.27M derived: sum of 2 quarters · filed 2023-02-21 | $312.51M derived: sum of 3 quarters · filed 2023-02-21 | $380.77M 10-K · filed 2023-02-21 |
| 2020-09-30 | $118.40M 10-Q · filed 2021-10-28 | $193.64M derived: sum of 2 quarters · filed 2021-10-28 | $261.90M 10-Q · filed 2021-10-28 | $358.36M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $75.24M 10-Q · filed 2021-07-29 | $143.50M 10-Q · filed 2021-07-29 | $239.96M derived: sum of 3 quarters · filed 2022-02-22 | $311.37M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $68.26M 10-Q · filed 2021-05-04 | $164.72M derived: sum of 2 quarters · filed 2022-02-22 | $236.13M derived: sum of 3 quarters · filed 2022-02-22 | |
| 2019-12-31 | $96.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $167.88M derived: sum of 2 quarters · filed 2022-02-22 | $306.98M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $71.42M 10-Q · filed 2020-10-29 | $210.52M 10-Q · filed 2020-10-29 | ||
| 2018-12-31 | $264.73M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |